{
    "clinical_study": {
        "@rank": "127776", 
        "arm_group": [
            {
                "arm_group_label": "Restylane\u00ae", 
                "arm_group_type": "Active Comparator", 
                "description": "Inject Restylane\u00ae on right or left nasolabial fold"
            }, 
            {
                "arm_group_label": "SkinPlus-Hyal\u00ae", 
                "arm_group_type": "Experimental", 
                "description": "Inject SkinPlus-Hyal\u00ae on right or left nasolabial fold"
            }
        ], 
        "brief_summary": {
            "textblock": "- Study design:Multi-center, randomized, double-masked (Unblinded treating investigators),\n      intra-individual comparison clinical trial"
        }, 
        "brief_title": "Efficacy and Safety Study of SkinPlus-Hyal\u00ae to Nasolabial Fold", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Wrinkle", 
        "detailed_description": {
            "textblock": "-  Subjects:Adults with nasolabial fold\n\n        -  Investigational Devices:\n\n      Study Device: SkinPlus-Hyal\u00ae Comparator Device: Restylane\u00ae\n\n      - Procedure Before Treatment: The subject's eligibility (inclusion/exclusion criteria) will\n      be assessed, and the WSRS of his/her nasolabial fold wil be evaluated by the Investigator\n      Treatment: The Injector will administer to the eligible subject the Study Device and\n      Comparator Device  respectively to the left and right nasolabial fold in a randomized\n      manner. Post-Treatment: All subjects will visit the hospital at 2, 8, 16, 24 weeks since the\n      day of administration, and will take pictures of the Nasolabial fold area and undergo\n      efficacy and safety evaluation during each visit. The Photographic evaluator will evaluate\n      the efficacy"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men and women aged over 20\n\n          2. Subjects who want to correct his/her nasolabial fold and have point 3 or 4 in WSRS of\n             nasolabial fold and visually symmetric\n\n          3. Subjects who voluntarily decided the participation of the study and signed the\n             informed consent\n\n          4. Subjects who agree contraception\n\n        Exclusion Criteria:\n\n          1. Subjects who had anaphylaxis or a severe combined allergy, or an allergy to\n             hyaluronic acid\n\n          2. Subjects who had eczema, infection, psoriasis, sclerosis, acne on the face\n\n          3. Subjects who have a skin disorder on the NLF area\n\n          4. Subjects who had permanent implants for dermal augmentation  at the NLF area\n\n          5. Subjects who had a history of keloid formation or hypertrophic scar\n\n          6. Subjects who participated in other clinical trial within 3 months from screening date\n\n          7. Female subjects of childbearing potential who disagreed with medically acceptable\n             contraception (e.g., condom, oral contraceptives continuing at least 3 months,\n             injectable or insertable contraceptives, intrauterine contraceptive devices) during\n             the trial\n\n          8. Subjects who is Drug abuser or alcoholism\n\n          9. Subjects who had previous treatment with Botox within 6 months from screening date\n\n         10. Subjects who had previous treatment for wrinkle with Retin-A within 1 months from\n             screening date\n\n         11. Subjects who had previous treatment with tissue restorative biomaterials within 18\n             months from screening date\n\n         12. Patients who are not eligible for this study at the medical discretion of the\n             Principal Investigator or Sub-investigator\n\n         13. Subjects who had antigen of HIV or type-B Hepatitis\n\n         14. Subjects who had anti-coagulant therapy within 2 weeks from the screening date\n\n         15. Patients who are not eligible for this study at the medical discretion of the\n             Principal Investigator or Sub-investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "123", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01940575", 
            "org_study_id": "E-1010-055-001", 
            "secondary_id": "06-2013-083"
        }, 
        "intervention": [
            {
                "arm_group_label": "SkinPlus-Hyal\u00ae", 
                "description": "The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.", 
                "intervention_name": "SkinPlus-Hyal\u00ae", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Restylane\u00ae", 
                "description": "The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.", 
                "intervention_name": "Restylane\u00ae", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Tissue restorative biomaterial", 
            "Hyaluronic acid", 
            "Restylane\u00ae", 
            "Wrinkle Severity Rating Scale (WSRS)", 
            "Global Aesthetic Improvement Scale (GAIS)", 
            "Nasolabial fold(NLF)"
        ], 
        "lastchanged_date": "April 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Seongnam-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "463-707"
                    }, 
                    "name": "Seoul national university Bundang Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jongno-gu", 
                        "country": "Korea, Republic of", 
                        "state": "Seoul", 
                        "zip": "110-744"
                    }, 
                    "name": "Seoul National University Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial to Evaluate the Safety and Efficacy of SkinPlus-Hyal\u00ae as Tissue Restorative Biomaterials in the Improvement of Bilateral Nasolabial Fold Wrinkles", 
        "other_outcome": {
            "description": "The percentage of subjects whose GAIS is 1 point or above at 2, 8, 16, 24 weeks after injection as assessed by the Investigator", 
            "measure": "The percentage of subjects whose GAIS is 1 point or above", 
            "safety_issue": "No", 
            "time_frame": "2, 8,16, 24  weeks"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Bundang Hospital", 
            "last_name": "Chanyeong - Heo, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The change in WSRS of the test group and control group from baseline at 24 weeks as assessed by the Investigator in charge of photographic assessment", 
            "measure": "The change in WSRS of the test group and control group", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01940575"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The change in WSRS of the test and control groups from baseline at 2, 8, 16, 24 weeks as assessed by the Investigator", 
            "measure": "The change in WSRS of the test and control groups", 
            "safety_issue": "No", 
            "time_frame": "baseline and 2, 8, 16, 24 weeks"
        }, 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "HumanTissueKorea Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}